Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

European Journal of Nuclear Medicine

Volumn 27, Issue 3, 2000, Pages 273-282

  Reubi, Jean Claude ^a   Schär, Jean Claude ^a   Waser, Beatrice ^a   Wenger, Sandra ^a   Heppeler, Axel ^b   Schmitt, Jörg S ^b   Mäcke, Helmut R ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Gallium labelled radioligands; Octreotate; Receptor affinity; Somatostatin receptor subtypes; Yttrium labelled radioligands

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANGIOPEPTIN; GALLIUM; INDIUM; OCTREOTIDE; PENTETREOTIDE; RADIOLIGAND; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; TRACER; VAPREOTIDE; YTTRIUM;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; GEOMETRY; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; LIGAND BINDING; RECEPTOR AFFINITY; RECEPTOR BINDING; SCINTIGRAPHY;

EID: 0034033495     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050034     Document Type: Article

References (34)

1. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, Ausema L, Lameris JS, Reubi JC, Lamberts SWJ. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; I:242-244.
2. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. New York: Raven Press, 1995.
3. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24:368-371.
4. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24:792-795.
5. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998; 351:417-418.
6. Smith-Jones P, Bischof C, Leimer D, Gludovacz D, Angelberger P, Pangerl T, Peck-Radosavljevic M, Hamilton G, Kaserer K, Steiner G, Schlagbauer-Wadl H, Mäcke H, Virgolini I. "Mauritius", a novel somatostatin analog for tumor diagnosis and therapy. J Nucl Med 1998; 39 Suppl:223P.
7. Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998; 39:1928-1936.
8. 0]octreotide. Eur J Nucl Med 1998; 25:182-186.
9. 188Re-RC-160, a directly-radiolabelled somatostatin analogue. Int J Cancer 1996; 65:214-220.
10. Heppeler A, Béhé M, Froidevaux S, Hennig M, Jermann E, Maecke HR. Metal coordination chemical aspects and tumor targeting of a promising somatostatin analogue. J Nucl Med 1998; 39 Suppl:63P.
11. 111In-labelled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998; 58:437-441.
12. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PPA, O'Carroll A, Patel YC, Schönbrunn A, Taylor JE, Reisine T. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16:86-88.
13. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995; 16:427-442.
14. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 mRNAs in primary human tumors using in situ hybridization. Cancer Res 1994; 54:3455-3459.
15. Schaer JC, Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sst1, sst2, sst3, and sst5 expression in human pituitary, gastroenteropancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997; 70:530-537.
16. Reubi JC, Schaer JC, Waser B, Hoeger C, Rivier J. A selective analog for the somatostatin receptor subtype sst1 expressed by human tumors. Eur J Pharmacol 1998; 345:103-110.
17. Atherton E, Sheppard RC. Fluorenylmethoxycarbonyl-polyamide solid phase peptide synthesis. General principles and development. Oxford: Information Press, 1989.
18. 1-octreotide synthesis. Bioconjug Chem 1997; 8:442-446.
19. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, Hennig M. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999; 5:1974-1981.
20. Béhé M, Heppeler A, Mäcke HR. New somatostatin analogs for SPECT and PET. Eur J Nucl Med 1996;:1144 No. OWe450.
21. Wetlaufer DB. Ultraviolet spectra of proteins and amino acids. In: Anfinsen CB Jr, Anson ML, Bailey K, Edsall JT, eds. Advances in protein chemistry. New York: Academic Press; 1962:303-378.
22. Rens-Domiano S, Reisine T. Biochemical and functional properties of somatostatin receptors. J Neurochem 1992; 58:1987-1996.
23. OCaroll A, Raynor K, Lolait SJ, Reisine T. Characterization of cloned human somatostatin receptor SSTR5. Mol Pharmacol 1994; 46:291-298.
24. 14 labels all five somatostatin receptors. Naunyn-Schmiedeberg's Arch Pharmacol 1998; 357:483-489.
25. Thoss VS, Pérez J, Probst A, Hoyer D. Expression of five somatostatin receptor mRNAs in the human brain and pituitary. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 354:411-419.
26. Reubi JC, Kvols LK, Waser B, Nagorney D, Heitz PU, Charboneau JW, Reading CC, Moertel C. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50:5969-5977.
27. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 1995; 36:1846-1853.
28. 68Ga] labelled DFO-octreotide (SDZ 216-927) for PET studies of somatostatin receptor positive tumors. Horm Metab Res 1994; 26:453-459.
29. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N, Susini C. Loss of sst2 receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996; 56:1823-1827.
30. Laws S, Gough AC, Evans AA, Bains MA, Primerose JN. Somatostatin receptors subtype mRNA expression in human colorectal cancer and normal colic mucosa. Br J Cancer 1997; 75:360-366.
31. Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 1994; 79:724-729.
32. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10:1688-1696.
33. Sharma K, Srikant CB. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998; 76:259-266.
34. Virgolini I, Pangerl T, Bischof C, Smith-Jones P, Peck-Radosavljevic M. Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? Eur J Clin Invest 1997; 27:645-647.